SOX2 and myeloid sarcoma: Furthermore, there was a notable decrease in SOX2+ cells and Olig2+ oligodendrocytes in MS organoids compared to controls, indicating a compromised capacity for differentiation and remyelination in MS patients and their subtypes [165].